Ardelyx (ARDX) investor relations material

Executive summary

• Achieved record Q2 2026 product revenue of $118.1 million, up 31% year-over-year, driven by strong demand for IBSRELA and XPHOZAH.

• Strategic focus on accelerating IBSRELA growth, maintaining XPHOZAH momentum, expanding the pipeline, and maintaining financial strength.

• On track for profitability in 2027, supported by robust commercial execution and disciplined capital allocation.

• Initiated Phase 3 trial for tenapanor in CIC, with topline data expected in 2027.

• XPHOZAH's inclusion in ESRD PPS has negatively impacted revenue growth due to loss of Medicare Part D coverage.

Financial highlights

• Total Q2 2026 product revenue was $118.1 million, up 31% year-over-year; IBSRELA revenue was $86.2 million (+33%), XPHOZAH revenue was $31.9 million (+27%).

• Net loss for Q2 2026 was $16.7 million ($0.07 per share), improved from $19.1 million ($0.08 per share) in Q2 2025.

• Cash, cash equivalents, and short-term investments totaled $281.8 million as of June 30, 2026.

• R&D expenses rose to $26.1 million (up 51–67% YoY); SG&A expenses increased to $101.4 million (up 21–22% YoY).

• Gross-to-net adjustment percentage increased to 34% in Q2 2026, reflecting unfavorable channel mix and inflation rebate charges.

Outlook and guidance

• FY 2026 IBSRELA revenue guidance revised to $350–$370 million; XPHOZAH guidance reiterated at $110–$120 million.

• Operating expense guidance revised to below $500 million.

• Profitability expected in 2027, with narrowing quarterly losses and expected sequential revenue growth in H2 2026.

• Long-term IBSRELA revenue target of $1 billion maintained, but timing under review; XPHOZAH long-term guidance withdrawn or under reassessment due to market uncertainty.

• Available liquidity expected to fund planned operations for at least one year from financial statement issuance.